Published by Coherent Market Insights
Posted on September 27, 2021
4 min readLast updated: February 2, 2026
The Acute Heart Failure Therapeutics Market is set for growth due to new drug approvals and technological advancements, with key players like Novartis leading the way.
Acute Heart Failure (AHF) Therapeutics Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Acute Heart Failure (AHF) Therapeutics Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.
Request for Sample Copy of Report at – https://www.coherentmarketinsights.com/insight/request-sample/1910
Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump enough blood through the heart to meet body’ optimal blood and oxygen level. Congestive heart failure is type of heart failure which requires timely medical attention. Moreover, distinguish between acute and chronic heart failure is important from a clinical standpoint, on which further medication depends. For this, N terminal proB-type natriuretic peptide levels are used for distinguishing acute versus chronic left ventricular dysfunction. An elevated levels of natriuretic peptide were present in patients with acute heart failure compared to those with chronic heart failure patient.
Heart failure symptoms vary widely from person to person, depending on types of heart failure patient. The main symptoms of heart failure are caused due to fluid accumulation or congestion and poor blood flow to the body. Symptoms caused by fluid accumulation or congestion includes shortness of breath, weight gain, coughing, swollen ankles, legs or abdomen, while dizziness, rapid heart rate, and fatigue are symptoms associated with reduced blood flow to parts of the body.
Acute Heart Failure (AHF) Therapeutics Market Drivers
The global acute heart failure therapeutics market is expected to witness significant growth due to approval of new drugs. For instance, in July 2015, Novartis received U.S. Food and Drug Administration (FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on the treatment of heart failure with reduced ejection fraction. Entresto is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.
Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another factor driving growth of acute heart failure therapeutics market. For instance, in March 2017, Cardioxyl Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now operates under the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’ acquisition by Bristol-Myers Squibb in December 2015); is present in Phase 2 clinical development phase. CXL-1427 is indicated to use as an intravenous treatment for acute decompensated heart failure (ADHF). Successful completion and further launch of Bristol-Myers Squibb’s innovative drug in future, will help to boost the acute heart failure (AHF) therapeutics market growth during the forecast period.
Major Key Players are: Novartis AG, Cardiorentis AG, Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc., among others. Key players in the marker are engaged in development of new drugs for acute heart failure (AHF). These players are incorporating collaboration strategies to remain competitive in the market.
Intent of the Acute Heart Failure (AHF) Therapeutics Market Research Study:
Purchase this Premium Report (Flat USD 2000 OFF) – https://www.coherentmarketinsights.com/promo/buynow/1910
Reasons to Purchase this Report
Contact US:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Acute Heart Failure (AHF) Therapeutics Market Growing Demand 2021 to 2027 | Coherent Market Insights appeared first on Gatorledger.
The article discusses the growth and demand in the Acute Heart Failure Therapeutics Market from 2021 to 2027.
Market growth is driven by new drug approvals and technological innovations in heart failure treatment.
Key players include Novartis AG, Bristol-Myers Squibb, and others involved in AHF drug development.
Explore more articles in the Research Reports category
